Evolus (EOLS) vs Eton Pharmaceuticals (ETON)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Eton Pharmaceuticals (ETON) has outperformed Evolus (EOLS) over the past year, gaining 161.6% versus a gain of 25.6%. Over five years, ETON leads with a +950.9% price change compared with +1.7% for EOLS. Eton Pharmaceuticals is the larger company by market cap ($1.56 billion vs $515.2 million), about 3.0 times the size.
On valuation, Eton Pharmaceuticals trades at a lower forward P/E (21.2x vs 26.7x for Evolus).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EOLS | ETON |
|---|---|---|
| Share price | $7.80 | $54.75 |
| Market cap | $515.19M | $1.56B |
| 1-day change | +0.78% | -0.24% |
| YTD return | +17.29% | +223.77% |
| 1-year return | +25.60% | +161.59% |
| 5-year return | +1.69% | +950.86% |
| P/E ratio (TTM) | — | 136.88 |
| Forward P/E | 26.67 | 21.22 |
| EPS (TTM) | $-0.53 | $0.40 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.31 | $66.37 |
| 52-week low | $3.86 | $14.27 |
| Distance from 52-week high | -16.22% | -17.51% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +92.31% | +29.68% |
| Average volume | 900.79K | 609.36K |
| Shares outstanding | 66.05M | 28.58M |
| Employees | 353 | 44 |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - Specialty & Generic |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Eton Pharmaceuticals is about 3.0 times larger than Evolus by market value ($1.56B vs $515.19M).
- ETON has outperformed EOLS by 136.0 percentage points over the past year.
About Evolus
EOLS stock →Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes.
Healthcare · Drug Manufacturers - Specialty & Generic · 353 employees
About Eton Pharmaceuticals
ETON stock →Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1.
Healthcare · Drug Manufacturers - Specialty & Generic · 44 employees
EOLS vs ETON FAQ
Which is bigger, Evolus or Eton Pharmaceuticals?
Eton Pharmaceuticals (ETON) is larger, with a market capitalization of $1.56B compared with $515.19M for Evolus (EOLS).
Which stock has performed better over the past year, EOLS or ETON?
ETON returned +161.59% over the past 12 months, compared with +25.60% for EOLS (price return, excluding dividends). Past performance does not predict future results.
Are Evolus and Eton Pharmaceuticals in the same industry?
Yes. Both are classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector.